Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders
Year: 2022
Type: review
Abstract: gene display improved neurobehavioral deficits, reduced neuropathology, and amelioration of neuronal cell death and inflammatory biomarkers. The significance of the compelling CTSB evidence is that the data consilience validates CTSB as a drug target for discovery of CTSB inhibitors as potential therapeutics for treating numerous neurological diseases.
Source: Pharmacological Reviews
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Awards: G105579614, Development of Molecular Probe Inhibitors of Pathogenic, Cytosolic Cathespin B in Traumatic Brain Injury and Alzheimers Disease Neurodegeneration, G2234928323, Elucidating new mechanism of brain barrier-synaptic disruptions caused by P. gingivitis, Cathepsin B inhibitor Drug Development for Traumatic Brain Injury, G6296468327, GRK 2606: Entschlüsselung zellulärer Proteasefunktionen durch Identifizierung und Analyse von Proteasesubstraten (ProtPath), Elucidation of Alzheimer's disease exacerbation mechanism of periodontitis centering on microglia-related neuroinflammation, G912826795, G913599493
OpenAlex ID: W4282983570
